NEW YORK (GenomeWeb News) – Varian today said that its shareholders have approved the firm's merger agreement with Agilent Technologies.

The deal, under which Agilent will acquire Varian for $52 per share in cash — for a total transaction value of around $1.5 billion — was announced in late July.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Researchers suggest that genetic variations could influence the side effects people experience when using synthetic cannabinoids, the International Business Times reports.

An analysis has examined the makeup of researchers on Twitter and what they share, Nature News reports.

At Stat News, Jim Kozubek argues that the Broad Institute is pushing the boundary of what a nonprofit is.

In PNAS this week: gut microbes may affect honeybee weight, phenotype and gene expression changes in DiGeorge syndrome, and more.